Research Solutions Inc. (NASDAQ:RSSS – Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 58,161 shares, a decrease of 47.2% from the August 15th total of 110,093 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 16,579 shares, the short-interest ratio is presently 3.5 days.
Analysts Set New Price Targets
A number of research firms have weighed in on RSSS. Weiss Ratings reissued a “hold (c-)” rating on shares of Research Solutions in a research report on Wednesday, August 12th. Lake Street Capital cut their price objective on Research Solutions from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.83.
View Our Latest Research Report on RSSS
Institutional Investors Weigh In On Research Solutions
Research Solutions News Roundup
Here are the key news stories impacting Research Solutions this week:
- Positive Sentiment: Maxim Group projects Research Solutions will remain profitable, with quarterly EPS estimates of $0.02 for most periods and $0.03 in fourth quarters. Its forecast implies FY2027 EPS of $0.10 and FY2028 EPS of $0.11, supporting expectations for continued earnings generation. Research Solutions stock information
- Neutral Sentiment: The estimates are broadly consistent across the multiple reports: Maxim forecasts $0.02 EPS in each of the first three quarters of fiscal 2027 and 2028, followed by $0.03 EPS in the fourth quarter. No new revenue outlook, strategic update, analyst recommendation, or valuation change was provided.
- Negative Sentiment: Maxim’s FY2027 and FY2028 EPS forecasts of $0.10 and $0.11, respectively, suggest only modest profit growth and remain below the company’s current-year consensus estimate of $0.12. This may limit upside enthusiasm, particularly after Research Solutions recently missed quarterly EPS expectations, reporting $0.02 versus a $0.04 consensus, despite slightly better-than-expected revenue.
Research Solutions Price Performance
Shares of Research Solutions stock traded down $0.01 during midday trading on Tuesday, hitting $1.97. The company had a trading volume of 131,296 shares, compared to its average volume of 58,644. The business’s 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $2.30. The stock has a market cap of $65.89 million, a PE ratio of 21.95 and a beta of 0.75. Research Solutions has a 1-year low of $1.92 and a 1-year high of $4.12.
Research Solutions (NASDAQ:RSSS – Get Free Report) last released its earnings results on Wednesday, September 9th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Research Solutions had a net margin of 5.84% and a return on equity of 16.32%. The company had revenue of $12.08 million for the quarter, compared to analyst estimates of $11.95 million. On average, sell-side analysts expect that Research Solutions will post 0.12 EPS for the current fiscal year.
Research Solutions Company Profile
Research Solutions, Inc (NASDAQ:RSSS) is a provider of software and managed services that streamline access to and management of scientific, technical and medical research. The company’s flagship platform automates the acquisition, licensing and delivery of journal articles, conference proceedings and other pay-walled content, enabling institutions to reduce administrative overhead and control subscription costs.
Key offerings include self-service workflows for document requests, enterprise-grade managed services for high-volume users, and analytics tools that deliver detailed reporting on spend, usage patterns and supplier performance.
Further Reading
- Five stocks we like better than Research Solutions
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Research Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Research Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
